Detailed interpretation of the drug instructions for gosatuzumab/Todavi

1. Drug introduction and mechanism characteristics

Gosatuzumab/Trodelvy (Trodelvy) is an antibody drug conjugate (ADC) targeting Trop-2. It is composed of a humanized monoclonal antibody and the chemotherapy drug SN-38 (the active metabolite of irinotecan) combined through a stable linker. Trop-2 is a transmembrane glycoprotein overexpressed in a variety of solid tumors, especially highly expressed in breast cancer, bladder cancer, etc. By targeting Trop-2, the drug accurately releases toxic drugs into cancer cells, thereby achieving stronger anti-tumor activity and lower systemic toxicity.

2. Main indications and population positioning

Currently,Trodelvy is approved for the following categories of patients:

1. Triple-negative breast cancer (mTNBC): Applicable to adult patients with locally advanced or metastatic triple-negative breast cancer. These patients must have received at least two systemic treatments, including treatment for the metastatic stage;

2. HR+/HER2- breast cancer: used for patients with hormone receptor-positive, HER2-negative unresectable or metastatic breast cancer who have received endocrine therapy in the past and two or more systemic therapies during the disease progression stage;

3. Urothelial carcinoma (mUC): Applicable to patients with locally advanced or metastatic urothelial cancer who need to progress despite platinum-based chemotherapy and PD-1/PD-L1 immunotherapy.

3. Usage and dosage analysis

1. Breast cancer usage: A 21-day treatment cycle is adopted, and intravenous injection is given on the 1st and 8th day, with a dose of 10 mg/kg each time. The dose is calculated based on the patient's weight, and treatment is continued until disease progression or unacceptable adverse reactions occur;

2. Bladder cancer and urinary system tumors: also follow the 21-day cycle, intravenous injection on days 1 and 8, each dose is 10 mg/kg, until disease progression or irreversible toxicity occurs;

3. Precautions: It is recommended to carry out anti-allergic pretreatment before medication, and closely monitor blood images, liver and kidney functions and potential side effects during treatment.

4. Tips on common adverse reactions

Although gosatuzumab is highly targeted, it can still cause some common side effects, including neutropenia, diarrhea, fatigue, nausea, and infusion reactions. EspeciallySN-38 related toxicity may lead to significant gastrointestinal reactions, so symptomatic treatment and dose adjustment are crucial.

5. Domestic market access and prospects

At present, gosatuzumab has been officially launched in China, mainly introduced by Gilead, and provides new treatment pathways in the fields of breast cancer and urinary system tumors. Although it has not yet been included in the national medical insurance catalog, its unique position in refractory solid tumors has led to its gradual expansion in clinical application. Access is expected to be further improved in the future through real-world research and health insurance access negotiations.

Summary: As an innovativeADC drug, gosatuzumab is reshaping the treatment landscape of some solid tumors with its precise targeting mechanism and potent anti-tumor effect. Its drug instructions clearly cover multiple indications and its clinical positioning is clear. It is an important solution worthy of attention after the failure of current multi-line treatments. With the gradual advancement of the domestic market, gosatuzumab may become a new treatment option for more Chinese patients.

Reference materials:https://www.trodelvy.com/